Halozyme Therapeutics: president and CEO Helen Torley exercised 60,000 shares

What happened

• Helen Torley, president and CEO and director, exercised options to acquire 20,000 shares on Oct 6, 20,000 shares on Oct 7 and 20,000 shares on Oct 8, 2026 (total 60,000 shares) at $18.41 per share for a total cost of $1,104,600. The filing also reports open-market/private sales of 20,000 shares on each of Oct 6, Oct 7 and Oct 8, 2026 (total 60,000 shares) for aggregate proceeds of $6,610,503.

Key details

• transaction dates and prices: exercises on Oct 6, Oct 7 and Oct 8, 2026 at $18.41 per share ($368,200 each); sales across those dates totaled $6,610,503 at prices roughly in the $107.48–$113.86 range (weighted-average prices and per-price breakdowns are given in the footnotes).
• shares owned after the transaction: not stated in the provided filing excerpt.
• relevant footnotes: the trades were made pursuant to a written Rule 10b5-1 trading plan adopted Dec 3, 2025; the shares sold were acquired following exercise of stock options with a ten-year term expiring Feb 2028 (grant dated Feb 14, 2018). Several footnotes report weighted-average sale prices and state that detailed per-price sale counts are available upon request.
• filing timeliness: Form 4 was filed on Oct 8, 2026; the filing does not indicate a late filing.

Why it may matter

• the filing shows options were exercised and the shares acquired were sold the same days (the filing reports exercises followed by sales).
• a filing does not show why the insider traded or why the company acted.